AtheroGenics Added to NASDAQ Biotech Index

AtheroGenics Added to NASDAQ Biotech Index 


ATLANTA, Nov. 14  /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a
pharmaceutical company focused on the treatment of chronic inflammatory
diseases, today announced that it has been selected to be added to the NASDAQ
Biotechnology Index  effective with the market open on Monday, November 24,
2003.

All securities in the Index are listed on the NASDAQ National Market and must be
classified according to the FTSE Global Classification System as either
biotechnology or pharmaceutical.  In addition, all securities in the Index must
meet minimum requirements for price, market value, average daily share volume
and seasoning as a public company.  The Index is ranked on a semi-annual basis
in May and November.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of
novel drugs for the treatment of chronic inflammatory diseases, including heart
disease (atherosclerosis), rheumatoid arthritis and asthma.  The Company has
four drug development programs in the clinic. AtheroGenics' lead compound,
AGI-1067, is being evaluated in the pivotal Phase III clinical trial called
ARISE (Aggressive Reduction of Inflammation Stops Events) as an oral therapy for
the treatment of atherosclerosis.  AGIX-4207, the Company's second clinical
compound derived from its proprietary v- protectant(TM) technology platform, is
a novel, oral agent being tested in a Phase II clinical program called OSCAR
(Oral Suppression of Cellular Inflammation Attenuates Rheumatoid Arthritis) as
an oral therapy for the treatment of rheumatoid arthritis.  AGIX-4207 I.V. is an
intravenous rheumatoid arthritis treatment that has completed a Phase I clinical
study. AGI-1096 is a novel, oral agent that has completed a Phase I clinical
trial for the prevention of organ transplant rejection.  For more information
about AtheroGenics, please visit http://www.atherogenics.com/ .

This press release may contain forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Such statements are subject to certain factors, risks and uncertainties that may
cause actual results, events and performances to differ materially from those
referred to in such statements. These risks include statements which address
operating performance, events or developments that we expect or anticipate will
occur in the future, such as projections about our future results of operations
or our financial condition, research, development and commercialization of our
product candidates, anticipated trends in our business, and other risks that
could cause actual results to differ materially.  These risks are discussed in
AtheroGenics' Securities and Exchange Commission filings, including but not
limited to the risks discussed in AtheroGenics' Form 10-K for fiscal 2002 and
our Quarterly Report on Form 10-Q for the second quarter of 2003. 

DATASOURCE: AtheroGenics, Inc.



CONTACT: Donna Glasky, Corporate Communications of AtheroGenics, Inc.,

[phone], or ; or Lilian Stern, of Stern

Investor Relations, [phone], or ; or Katie Brazel,

Media Relations of Fleishman Hillard, [phone], or





Web site:  http://www.atherogenics.com/

Copyright